1Youlden DR, Cramb SM, Baade PD. The international epidemiology of lungcancer: geographical distribution and secular trends. J Thorac Oncol, 2008,3(8):819-831.
3Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung diseaseand its association with lung cancer. Br J Cancer, 2004, 91(2): S3-S10.
4Miyazaki K, Satoh H, Kurishima K, et al Interstitial lung disease in patientswith small cell lung cancer. Med Oncol, 2010, 27(3): 763-767.
5Schwaiblmair M, Behr W, Haeckel T, et al. Drug induced interstitial lungdisease. Open Respir Med J, 2012,6(6): 63-74.
6Tsuboi M, Le Chevalier T. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors.Med Oncol, 2006, 23(2): 161-170.
7Tamiya A, Naito T,Miura S, et al. Interstitial lung disease associated withdocetaxel in patients with advanced non-small cell lung cancer. AanticancerRes, 2012, 32(3): 1103-1106.
8Okuda K, Hirose T, Oki Y, et al. Evaluation of the safety and efficacy ofcombination chemotherapy with vinorelbine and platinum agents forpatients with non-small cell lung cancer with interstitial lung disease.Anticancer Res, 2012, 32(12): 5475-5480.
9Shukuya T, Ishiwata T, Hara M, et al. Carboplatin plus weekly paclitaxeltreatment in non-small cell lung cancer patients with interstitial lung disease.Anticancer Res, 2010, 30(10): 4357-4361.
10Umemura S, Yamane H, Suwaki T, et al. Interstitial lung disease associatedwith gemcitabine treatment in patients with non-small-cell lung cancer andpancreatic cancer. J Cancer Res Clin Oncol, 2011,137(10): 1469-1475.
